Parkinson's Disease Levodopa-Induced Dyskinesia Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Key Companies - PharmaTher, Neurolixis, Gala laboratories, Contera Pharma, Vistagen, Ipsen, Newron, Zambon

Parkinson's Disease Levodopa-Induced Dyskinesia Market size in the 7MM was approximately USD 1,500 million in 2021, which is expected to grow by 2032. As per DelveInsight, the Parkinson's Disease Levodopa-Induced Dyskinesia Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases and the launch of new therapies in the market.

DelveInsight's "Parkinson's Disease Levodopa-Induced Dyskinesia Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Parkinson's Disease Levodopa-Induced Dyskinesia Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Parkinson's Disease Levodopa-Induced Dyskinesia therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Parkinson's Disease Levodopa-Induced Dyskinesia treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Parkinson's Disease Levodopa-Induced Dyskinesia: An Overview
Parkinson's disease (PD) is a life-threatening progressive neurodegenerative disease characterized by severe locomotor impairments, including bradykinesia, tremor, and rigidity. Other abnormalities associated with PD are cognitive defects, psychiatric abnormalities, and neurodegenerative implications of levodopa-induced dyskinesia (LID).

Levodopa (L-DOPA) is highly efficient and is used to mitigate PD, but its prolonged use gives rise to motor abnormalities, including dyskinesia. Dyskinesia may be mild at first but may develop into a debilitating symptom and affect patients' quality of life. More than 50% of patients with PD develop LID after 5 years of continuous treatment with L-DOPA, which worsens the quality of life in these patients.

PD-LID is clinically heterogeneous as there are three variants: peak-dose dyskinesia, off-period dystonia, and diphasic dyskinesias; they commonly present as chorea or choreoathetosis, though myoclonus, akathisia, ballism, and other abnormal movements have also been described. Different scales and instruments have been used to objectively assess PD-LID and its impact on the overall quality of life. The scales used to assess PD-LID, include the Rush Dyskinesia Rating Scale (RDRS), Unified Dyskinesia Rating Scale, Clinical Dyskinesia Rating Scale (CDRS), and Unified Parkinson's Disease Rating Scale (UPDRS).

Parkinson's Disease Levodopa-Induced Dyskinesia Market Key Facts
• In 2022, the highest number of cases were observed in the United States, followed by Germany, France, and others. The cases are expected to increase during the forecast period.
• Among the 7MM, France accounted for nearly 9% of PD-LID cases in 2022. The cases are expected to increase at a CAGR of approximately 0.8% by 2032
• According to DelveInsight analysts, in 2022, the number of cases of peak-dose dyskinesia was around 35,786, followed by off-period dystonia with nearly 13,420 cases, and diphasic dyskinesia with almost 8,946 cases in Japan.
• Spain accounted for about 41,324 cases of PD-LID in 2022, which are expected to rise during the forecast period.
• Major players include PharmaTher, Neurolixis SAS/Gala laboratories, Bukwang Pharmaceutical/Contera Pharma, Vistagen, Ipsen Pharma, Newron Pharmaceuticals/Zambon Pharmaceuticals, and Celon Pharma SA, whose key products are expected to get launched in the US market in the near future.

Discover How Parkinson's Disease Levodopa-Induced Dyskinesia Market Will Grow by 2032:
https://www.delveinsight.com/report-store/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Parkinson's Disease Levodopa-Induced Dyskinesia Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Parkinson's Disease Levodopa-Induced Dyskinesia therapies in the market. It also provides a detailed assessment of the Parkinson's Disease Levodopa-Induced Dyskinesia market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Parkinson's Disease Levodopa-Induced Dyskinesia drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Parkinson's Disease Levodopa-Induced Dyskinesia Epidemiology
The epidemiology section covers detailed insights into the historical, and current Parkinson's Disease Levodopa-Induced Dyskinesia patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Parkinson's Disease Levodopa-Induced Dyskinesia Epidemiology Segmented as -
• Total Diagnosed Prevalent Cases of Parkinson's Disease in the 7MM [2019-2032]
• Age-specific Cases of Parkinson's Disease in the 7MM [2019-2032]
• Type-specific Cases of PD-LID in the 7MM [2019-2032]
• Total Cases of Parkinson's Disease Patients on Levodopa in the 7MM [2019-2032]
• Total Cases of Parkinson's Disease Levodopa-induced Dyskinesia (PD-LID) in the 7MM [2019-2032]

Get Key Insights Into the Evolving Parkinson's Disease Levodopa-Induced Dyskinesia Epidemiology Trends @
https://www.delveinsight.com/report-store/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Parkinson's Disease Levodopa-Induced Dyskinesia Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Parkinson's Disease Levodopa-Induced Dyskinesia market or expected to be launched during the study period. The analysis covers the market share by Parkinson's Disease Levodopa-Induced Dyskinesia drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Parkinson's Disease Levodopa-Induced Dyskinesia Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities @
https://www.delveinsight.com/sample-request/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Parkinson's Disease Levodopa-Induced Dyskinesia Therapeutics Assessment
At present, there exists no authorized medicinal treatment for Levodopa-Induced Dyskinesia (LID) that effectively enhances daily functioning, elevates life quality, and alleviates the responsibilities of caregivers. While many individuals with Parkinson's Disease can endure medications like amantadine IR and NOURIANZ, using them alongside levodopa might induce or worsen dyskinesia that already exists. Yet, once LID manifests, it becomes a permanent condition, and discontinuing L-DOPA treatments can exacerbate motor symptoms, rendering the management of LID challenging.

Leading Companies in the Parkinson's Disease Levodopa-Induced Dyskinesia Therapeutics Market Include
• PharmaTher Inc.
• Neurolixis SAS
• Gala laboratories
• Bukwang Pharmaceutical
• Contera Pharma
• Vistagen
• Ipsen Pharma
• Newron Pharmaceuticals
• Zambon Pharmaceuticals
• Celon Pharma SA
And Many Others

Emerging and Marketed Parkinson's Disease Levodopa-Induced Dyskinesia Therapies Covered in the Report Include
• KETARX (PharmaTher)
• NLX-112 (Neurolixis SAS/Gala laboratories)
• JM-010 (Bukwang Pharmaceutical/Contera Pharma)
• AV-101 (Vistagen), Mesdopetam (Ipsen Pharma)
• XADAGO (Newron Pharmaceuticals/Zambon Pharmaceuticals)
• CPL500036 (Celon Pharma SA)
And Many More

Learn More About the Emerging Therapies & Key Companies in the Parkinson's Disease Levodopa-Induced Dyskinesia Therapeutics Market:
https://www.delveinsight.com/sample-request/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Parkinson's Disease Levodopa-Induced Dyskinesia Competitive Intelligence Analysis
4. Parkinson's Disease Levodopa-Induced Dyskinesia Market Overview at a Glance
5. Parkinson's Disease Levodopa-Induced Dyskinesia Background and Overview
6. Parkinson's Disease Levodopa-Induced Dyskinesia Patient Journey
7. Parkinson's Disease Levodopa-Induced Dyskinesia Epidemiology and Patient Population
8. Parkinson's Disease Levodopa-Induced Dyskinesia Treatment Algorithm, Current Treatment, and Medical Practices
9. Parkinson's Disease Levodopa-Induced Dyskinesia Unmet Needs
10. Key Endpoints of Parkinson's Disease Levodopa-Induced Dyskinesia Treatment
11. Parkinson's Disease Levodopa-Induced Dyskinesia Marketed Products
12. Parkinson's Disease Levodopa-Induced Dyskinesia Emerging Therapies
13. Parkinson's Disease Levodopa-Induced Dyskinesia Seven Major Market Analysis
14. Attribute Analysis
15. Parkinson's Disease Levodopa-Induced Dyskinesia Market Outlook (7 major markets)
16. Parkinson's Disease Levodopa-Induced Dyskinesia Access and Reimbursement Overview
17. KOL Views on the Parkinson's Disease Levodopa-Induced Dyskinesia Market.
18. Parkinson's Disease Levodopa-Induced Dyskinesia Market Drivers
19. Parkinson's Disease Levodopa-Induced Dyskinesia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Healthcare Consulting and Competitive Intelligence Services by DelveInsight
Discover DelveInsight's Comprehensive Market Research and Consulting Services:
https://www.delveinsight.com/market-research

Elevate your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics, at:
https://www.delveinsight.com/medical-devices

Empowering Cancer Care: DelveInsight's oncology consulting services offer personalized guidance and cutting-edge expertise to navigate the ongoing clinical, commercial, and regulatory developments, visit for more details:
https://www.delveinsight.com/oncology

Other Trending Healthcare Reports by DelveInsight
Tenosynovitis Market
https://www.delveinsight.com/report-store/tenosynovitis-market

Checkpoint Inhibitor Refractory Cancer Market
https://www.delveinsight.com/report-store/checkpoint-inhibitor-refractory-cancer-market

Encephalomyelitis Market
https://www.delveinsight.com/report-store/encephalomyelitis-market

FENEBRUTINIB Market
https://www.delveinsight.com/report-store/fenebrutinib-emerging-insight-and-market-forecast

Non-Muscle Invasive Bladder Cancer Market
https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-market

Nrg1 Fusion Cancer Pipeline Insight
https://www.delveinsight.com/report-store/nrg1-fusion-cancer-pipeline-insight

Acute Pyelonephritis Market
https://www.delveinsight.com/report-store/acute-pyelonephritis-market

Chronic Refractory Gout Market
https://www.delveinsight.com/report-store/chronic-refractory-gout-market

Complicated Urinary Tract Infections Market
https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-market

Congestive Heart Failure (CHF) Market
https://www.delveinsight.com/report-store/congestive-heart-failure-market

Glomerulonephritis Market
https://www.delveinsight.com/report-store/glomerulonephritis-market

Metastatic Uveal Melanoma (MUM) Market
https://www.delveinsight.com/report-store/metastatic-uveal-melanoma-mum-market

Musculoskeletal Pain Market
https://www.delveinsight.com/report-store/musculoskeletal-pain-market

Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market
https://www.delveinsight.com/report-store/recurrent-head-and-neck-cancer-squamous-cell-carcinoma-market

Dysthymia Market
https://www.delveinsight.com/report-store/dysthymia-market

Limb Girdle Muscular Dystrophy (LGMD) Market
https://www.delveinsight.com/report-store/limb-girdle-muscular-dystrophy-lgmd-market

Lower-Limb Spasticity Market
https://www.delveinsight.com/report-store/lower-limb-spasticity-market

Hemiplegia Market
https://www.delveinsight.com/report-store/hemiplegia-market

Global Kinase Inhibitor in Autoimmune Diseases Market
https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market

Hereditary Spastic Paraplegias Market
https://www.delveinsight.com/report-store/hereditary-spastic-paraplegias-market

Amebiasis Market
https://www.delveinsight.com/report-store/amebiasis-market

Galactosemia Market
https://www.delveinsight.com/report-store/galactosemia-market

Generalized Pustular Psoriasis Market
https://www.delveinsight.com/report-store/generalized-pustular-psoriasis-market

Hepatic Impairment Market
https://www.delveinsight.com/report-store/hepatic-impairment-market

Tuberous Sclerosis Complex Market
https://www.delveinsight.com/report-store/tuberous-sclerosis-complex-market

Amyloidosis Market
https://www.delveinsight.com/report-store/amyloidosis-market

BRAF-Mutant Metastatic Melanoma Market
https://www.delveinsight.com/report-store/braf-mutant-metastatic-melanoma-market

Candidemia Market
https://www.delveinsight.com/report-store/candidemia-market

Hepatitis D Market
https://www.delveinsight.com/report-store/hepatitis-d-market

Hyperkalemia Market
https://www.delveinsight.com/report-store/hyperkalemia-market

Vasomotor symptoms (Hot flashes/Night sweats) Market
https://www.delveinsight.com/report-store/vasomotor-symptoms-market

Balloon Valvuloplasty Device Market
https://www.delveinsight.com/report-store/balloon-valvuloplasty-market

Choroideremia Market
https://www.delveinsight.com/report-store/choroideremia-market

Chronic Hand Eczema Market
https://www.delveinsight.com/report-store/chronic-hand-eczema-market

Complex Regional Pain Syndrome Market
https://www.delveinsight.com/report-store/complex-regional-pain-syndrome-crps-market

Diffuse Large B-cell Lymphoma Market
https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market

Hypersomnia Market
https://www.delveinsight.com/report-store/hypersomnia-market

Lamellar Ichthyosis (LI) Market
https://www.delveinsight.com/report-store/lamellar-ichthyosis-market

Ulcerative Colitis (UC) Market
https://www.delveinsight.com/report-store/ulcerative-colitis-uc-market

Vernal Keratoconjunctivitis Market
https://www.delveinsight.com/report-store/vernal-keratoconjunctivitis-market-insight

Endocarditis Market
https://www.delveinsight.com/report-store/endocarditis-market

Essential Thrombocythemia (ET) Market
https://www.delveinsight.com/report-store/essential-thrombocythemia-et-market-insights

Hepatorenal Syndrome Market
https://www.delveinsight.com/report-store/hepatorenal-syndrome-market

Pancreatic Ductal Carcinoma Market
https://www.delveinsight.com/report-store/pancreatic-ductal-carcinoma-market

Tenosynovial Giant Cell Tumors (TSGCTs) Market
https://www.delveinsight.com/report-store/tenosynovial-giant-cell-tumors-tsgcts-market

Trauma Fixation Devices Market
https://www.delveinsight.com/report-store/trauma-devices-market

Usher Syndrome Market
https://www.delveinsight.com/report-store/usher-syndrome-market

Vulvar Squamous Cell Carcinoma Market
https://www.delveinsight.com/report-store/vulvar-squamous-cell-carcinoma-market

Wide Neck Bifurcation Intracranial Aneurysms Market
https://www.delveinsight.com/report-store/wide-neck-bifurcation-intracranial-aneurysms-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.